| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/27/2003 | WO2002098865A3 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
| 02/27/2003 | WO2002098413A3 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof |
| 02/27/2003 | WO2002098399A3 Cancer treatment method and compositions comprising compounds of the ginger family |
| 02/27/2003 | WO2002098354A3 Compositions and methods for inhibiting bone resorption |
| 02/27/2003 | WO2002098353A3 Compositions and methods for inhibiting bone resorption |
| 02/27/2003 | WO2002098350A3 Pyranoindazoles and their use for the treatment of glaucoma |
| 02/27/2003 | WO2002096398A3 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 02/27/2003 | WO2002095704A9 Use of nf-kappa-b inhibitors to treat dry eye disorders |
| 02/27/2003 | WO2002094188A3 Methods for regulating bacteria |
| 02/27/2003 | WO2002094183A3 A method for tumor treatment with fumagillol derivatives |
| 02/27/2003 | WO2002094180A3 Pharmaceutically active isoindoline derivatives |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 02/27/2003 | WO2002091992A3 Targeted delivery of drugs for the treatment of parasitic infections |
| 02/27/2003 | WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists |
| 02/27/2003 | WO2002089813A3 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/27/2003 | WO2002089749A3 Arylsulfonamide ethers, and methods of use thereof |
| 02/27/2003 | WO2002089745A3 Substituted n'-(arylcarbonyl)-benzhydrazides, n'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/27/2003 | WO2002089740A3 Sulfonamides |
| 02/27/2003 | WO2002087553A3 Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops |
| 02/27/2003 | WO2002087517A3 Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin |
| 02/27/2003 | WO2002087472A8 Stent-based delivery of statins to prevent restenosis |
| 02/27/2003 | WO2002087423A3 Carbonic anhydrase activators for enhancing learning and memory |
| 02/27/2003 | WO2002085903A3 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 02/27/2003 | WO2002085301A3 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 02/27/2003 | WO2002083135A3 Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
| 02/27/2003 | WO2002083064A3 A method of treating cancer |
| 02/27/2003 | WO2002079149A3 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 02/27/2003 | WO2002076401A3 Method of attenuating reactions to skin irritants |
| 02/27/2003 | WO2002074288A3 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide |
| 02/27/2003 | WO2002074050A3 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 02/27/2003 | WO2002074042A3 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 02/27/2003 | WO2002072542A3 Ph-dependent nmda receptor antagonists |
| 02/27/2003 | WO2002072018A3 A cream-t0-powder dermatological composition |
| 02/27/2003 | WO2002069903A3 Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| 02/27/2003 | WO2002068383A3 Thiol-modified hyaluronan |
| 02/27/2003 | WO2002067869A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/27/2003 | WO2002066420A3 Tryptase inhibitors |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002062334A3 Cancer chemopreventative compounds and compositions and methods of treating cancers |
| 02/27/2003 | WO2002062321A3 Method for producing a floating tablet containing an active principle |
| 02/27/2003 | WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002060374A3 Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
| 02/27/2003 | WO2002058634A3 ESTRADIOL-16α-CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
| 02/27/2003 | WO2002056835A3 Anticancer treatment using triptolide prodrugs |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002055093A3 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
| 02/27/2003 | WO2002055022A3 Active metabolite of antifungal compound |
| 02/27/2003 | WO2002049611A3 Ophthalmic lubricating solution adapted for use in lasik surgery |
| 02/27/2003 | WO2002049577A3 Analogues of thiocoraline and be-22179 |
| 02/27/2003 | WO2002046193A3 Heterocyclic ether substituted imidazoquinolines |
| 02/27/2003 | WO2002044184A3 Dna methyl transferase inhibitors |
| 02/27/2003 | WO2002040477A3 Saframycins, analogues and uses thereof |
| 02/27/2003 | WO2002038157A3 Inhibitors of thromboxane formation and action |
| 02/27/2003 | WO2002038105A3 Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| 02/27/2003 | WO2002030469A3 Beta-lactam antibiotic-polysaccharide complex |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002028379A3 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 02/27/2003 | WO2002022111A3 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 02/27/2003 | WO2002020000A3 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 02/27/2003 | WO2002019964A3 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions |
| 02/27/2003 | WO2002017919A3 Use of threo-methylphenidate compounds to enhance memory |
| 02/27/2003 | WO2002011711A3 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 02/27/2003 | WO2002008267A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/27/2003 | WO2002004605A3 Stimulation of cellular regeneration and differentiation in the inner ear |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2001098543A3 Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 02/27/2003 | WO2001098267A8 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity |
| 02/27/2003 | WO2001097861A3 Vitronectin receptor antagonist pharmaceuticals |
| 02/27/2003 | WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 02/27/2003 | WO2001075164A3 Rna sequence-specific mediators of rna interference |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection |
| 02/27/2003 | US20030040631 As chemical intermediates used for the preparation of S-alpha-ethyl-2-oxo-1-pyrrolidine acetamide |
| 02/27/2003 | US20030040625 For therapy of hypertension, type 2 insulin-resistant diabetes mellitus, ecalmpsia and preeclampsia |
| 02/27/2003 | US20030040543 Hydroxyurea treatment for spinal muscular atrophy |
| 02/27/2003 | US20030040542 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| 02/27/2003 | US20030040541 Administering bismuth subgallate to inhibit the production of nitric oxide synthases (NOS) |
| 02/27/2003 | US20030040539 Administering melatonin for therapy of dependence on, tolerance of, or addiction to at least one benzodiazepine compound |
| 02/27/2003 | US20030040537 Treatment of migraine headache |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040534 For therapy of pulmonary hypertension, particularly primary pulmonary hypertension; benign prostatic hypertrophy; migraine; renal, glomerular or mesangial cell disorders; endotoxemia; ischemia; atherosclerosis; restenosis |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040532 Methods for treating dementia due to HIV disease |
| 02/27/2003 | US20030040531 For therapy and prophylaxis of reperfusion injury |
| 02/27/2003 | US20030040530 Phenoxypropanolamines, method for producing them and pharmaceutical compositions containning them |
| 02/27/2003 | US20030040529 Combined agents for treatment of glaucoma |
| 02/27/2003 | US20030040528 For relieving or preventing constipation in a human constipated patient or preparing a bowel prior to preventative, diagnostic or surgical procedures |
| 02/27/2003 | US20030040526 Administering therapy regiment comprising at least one cycle of eflomithine, matulane and a nitrosourea for therapy of anaplastic glioma |
| 02/27/2003 | US20030040524 Pyrimidine compounds and methods for making and using the same |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040522 Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon) |
| 02/27/2003 | US20030040519 Use of serotonergic compound for a method of treatment of hot flushes in post-menopausal women |
| 02/27/2003 | US20030040518 For therapy of neurodegenerative diseases and for the regeneration or prevention of degeneration of lesioned and damaged neurons degeneration of lesioned and damaged neurons |
| 02/27/2003 | US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases |
| 02/27/2003 | US20030040514 Combination effective for the treatment of impotence |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040512 Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances |